SRA 737

Drug Profile

SRA 737

Alternative Names: CCT 245737; PNT737; SRA737

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Cancer Research Technology; Sareum; The Institute of Cancer Research
  • Developer The Institute of Cancer Research
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Checkpoint kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 02 Mar 2017 Sierra Oncology plans combination trials of SRA 737 with PARP inhibitors and immuno-oncology agents for Cancer
  • 09 Jan 2017 ProNAi Therapeutics is now called Sierra Oncology
  • 27 Sep 2016 ProNAi in-licenses exclusive worldwide rights to PNT 737 from Cancer Research Technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top